Clinical trial
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine (CONQUER)
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine (CONQUER)
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 463 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Actual Study Start Date: July 31, 2018
Actual Primary Completion Date: June 19, 2019
Actual Study Completion Date: September 23, 2019
Arms:
- Experimental: Galcanezumab
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 463 |
| Study start date | 31 July 2018 |
| Actual study completion date | 23 September 2019 |